Gemini Therapeutics Stock (NASDAQ:GMTX)
Previous Close
$1.35
52W Range
$1.35 - $24.70
50D Avg
$16.65
200D Avg
$15.80
Market Cap
$25.49M
Avg Vol (3M)
$22.36K
Beta
-
Div Yield
-
GMTX Company Profile
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.